Anika Therapeutics Q3 2026 Results: Net Loss of $311K, Loss Narrows
Anika Therapeutics reported a 10% revenue increase to $30.6 million for the third quarter of 2026, driven by its strategic shift toward OA pain management and regenerative solutions. Despite the revenue growth, the company recorded a net loss of $0.3 million for the quarter, though this was a significant improvement from the $2.3 million net loss in the prior year period.
- Key figure
- Net loss $311K